5Suppliers
20Customers
3Debt Items
0Related Chains

Source-Backed Evidence Depth

OSR Holdings, Inc. (OSRH) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

28Total relationships
6Distinct source URLs
10High confidence
0.716Average confidence
2026-07-01Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

OSR Holdings, Inc. Suppliers

TickerNameConfidenceEvidence
VAXIMM-AG VAXIMM-AG 92% Vaximm agreed to sell, and the Company agreed to purchase, free and clear of all encumbrances, all of Vaximm's right, title and interest in and to the VXM01 intellectual property family
BCM-EUROPE-AG BCM-EUROPE-AG 90% The Global Exclusive License Agreement entered into among the Company, Vaximm AG, and BCM Europe AG.
OSR-HOLDINGS-CO-LTD OSR-HOLDINGS-CO-LTD 90% Mr. Kim, age 36, most recently served as a Senior Analyst at OSR Holdings Co., Ltd., a subsidiary of the Company, from 2020 to 2025, where he supported the Company and its subsidiaries’ cross-border …
WOORI-IO-CO-LTD WOORI-IO-CO-LTD 90% The Parent acquired subsidiary in January 26, 2026 and accounted for the acquisitions at January 1, 2026, which is deemed the acquisition date.
DUKSUNG-CO-LTD DUKSUNG-CO-LTD 80% The Group has a loan agreement with Duksung Co., Ltd and as of March 31, 2026, the outstanding balance was $ 650,000

OSR Holdings, Inc. Customers

TickerNameConfidenceEvidence
BCM-EUROPE-AG BCM-EUROPE-AG 92% BCME is obligated to pay the Company milestone payments of up to $815,000,000 in the aggregate upon the achievement of specified clinical, regulatory, and commercial milestones.
SALES-GROSS-PROFIT-OSR-HOLDINGS SALES-GROSS-PROFIT-OSR-HOLDINGS 85% 28,888,361 ) -16,995,683 143 % 106 Net Sales, Cost of Sales, Gross Profit OSR Holdings’ net sales, cost of sales, and gross profit are primarily derived from RMC, its subsidiary engaged in the distri…
BELLEVUE-CAPITAL-MANAGEMENT-LLC BELLEVUE-CAPITAL-MANAGEMENT-LLC 62% . Accordingly, management expects this consignment-based model to enhance the stability of gross profit margins in future periods. Selling, General and Administrative Expenses For the three months en…
BELLEVUE-GLOBAL-LIFE-SCIENCES-INVESTORS-LLC BELLEVUE-GLOBAL-LIFE-SCIENCES-INVESTORS-LLC 62% average exercise price of outstanding options, warrants and rights Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in colu…
BENJAMIN-SECURITIES-INC BENJAMIN-SECURITIES-INC 62% may be the target of securities class action and derivative lawsuits which could result in substantial costs. Our share price may be volatile and, in the past, companies that have experienced volatil…
CHARDAN-CAPITAL-MARKETS-LLC CHARDAN-CAPITAL-MARKETS-LLC 62% may be the target of securities class action and derivative lawsuits which could result in substantial costs. Our share price may be volatile and, in the past, companies that have experienced volatil…
CO-LTD CO-LTD 62% n Co., Ltd. (“Darnatein”) 4,506,702 100.00 % Biotech (drug development) OSR Holdings, Inc. (“OSRI”) (*1) 2,687 100.00 % SPAC Key financial information of the subsidiaries at December 31, 2025 are as …
DONOHOE-ADVISORY-ASSOCIATES-LLC DONOHOE-ADVISORY-ASSOCIATES-LLC 62% Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations The following discussion and analysis of our financial condition and results of operations should be read…
DUKSUNG-CO-LTD DUKSUNG-CO-LTD 62% ows: For the year ended December 31, 2025 Beginning Business combination Impairment loss Effects of changes in exchange rate Ending Goodwill $ 24,354,066 $ - $ - $ 595,740 $ 24,949,806 For the year e…
EXPENSE-OSR-HOLDINGS EXPENSE-OSR-HOLDINGS 62% . Accordingly, management expects this consignment-based model to enhance the stability of gross profit margins in future periods. Selling, General and Administrative Expenses For the three months en…
KOREA-TECHNOLOGY-FINANCE-CORPORATION KOREA-TECHNOLOGY-FINANCE-CORPORATION 62% ning Business combination Impairment loss Effects of changes in exchange rate Ending Goodwill $ 24,949,806 $ 6,405,124 $ - $ ( 1,626,379 ) $ 29,728,552 For the three-months ended March 31, 2025 Begin…
LEASES-THE-GROUP LEASES-THE-GROUP 62% n Co., Ltd. (“Darnatein”) 4,506,702 100.00 % Biotech (drug development) OSR Holdings, Inc. (“OSRI”) (*1) 2,687 100.00 % SPAC Key financial information of the subsidiaries at December 31, 2025 are as …
OSR-HOLDINGS OSR-HOLDINGS 62% . Accordingly, management expects this consignment-based model to enhance the stability of gross profit margins in future periods. Selling, General and Administrative Expenses For the three months en…
OSR-HOLDINGS-CO-LTD OSR-HOLDINGS-CO-LTD 62% er 31, 2025. The Parent has entered into various contractual commitments related to the acquisition of VAXIMM including a future financial obligation of CHF 28,898 underlying as of March 31, 2026. Me…
OVERVIEW-OSR-HOLDINGS-INC OVERVIEW-OSR-HOLDINGS-INC 62% Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations The following discussion and analysis of our financial condition and results of operations should be read…
R-D-EXPENSES-OSR-HOLDINGS R-D-EXPENSES-OSR-HOLDINGS 62% . Accordingly, management expects this consignment-based model to enhance the stability of gross profit margins in future periods. Selling, General and Administrative Expenses For the three months en…
TACTION-CO-LTD TACTION-CO-LTD 62% rest income $ 63,883 $ 21,294 Foreign exchange gains 48,472 37,419 Gains on foreign currency translation 46,018 38,416 Interest expense ( 506,196 ) ( 51,335 ) Losses on foreign currrency transaction …
VAXIMM-AG VAXIMM-AG 62% n Co., Ltd. (“Darnatein”) 4,506,702 100.00 % Biotech (drug development) OSR Holdings, Inc. (“OSRI”) (*1) 2,687 100.00 % SPAC Key financial information of the subsidiaries at December 31, 2025 are as …
WHITE-LION-CAPITAL-LLC WHITE-LION-CAPITAL-LLC 62% merger-related expenses were one-time in nature and did not involve cash outflows. Loss Before Income Taxes For the year ended December 31, 2025, OSR Holdings’ loss before income taxes increased by $…
WOORI-IO-CO-LTD WOORI-IO-CO-LTD 62% as to the insurance coverage and reimbursement status of any products for which we may obtain regulatory approval. In the United States, sales of any products for which we may receive regulatory appr…

OSR Holdings, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
OSRH-DEBT-11604 Xbrl Convertible 90% xbrl convertible detail from xbrl 2025-12-31.
OSRH-DEBT-11603 Warrants outstanding: 1236527 90% xbrl warrant detail from xbrl 2023-12-31.
OSRH-DEBT Debt stack $5.0M 90% Market cache reports total debt of $5.0M.

OSR Holdings, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for OSR Holdings, Inc..

OSR Holdings, Inc. Ownership

No ownership data on recordNo major institutional ownership relationships found in our database for OSR Holdings, Inc..

OSR Holdings, Inc. Extended Supply Chain Network

No secondary connectionsNo correlated companies found through shared supply chain relationships.
🔐
OSRH
Unlock OSRH Supply Chain Data
Verified relationships include:
VAXIMM-AGVAXIMM-AGSupplier92%
BCM-EUROPE-AGBCM-EUROPE-AGSupplier90%
BCM-EUROPE-AGBCM-EUROPE-AGCustomer92%
SALES-GROSS-PROFIT-OSR-HOLDINGSSALES-GROSS-PROFIT-OSR-HOLDINGSCustomer85%
+24 more relationships locked
Subscribe — View plans →